隶属于 st bartholomew's hospital medical college
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2003
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Forskolin, a natural plant compound, demonstrates dual anti-leukemic activity by directly slowing cancer cell growth and enhancing chemotherapy effectiveness in KMT2A-rearranged AML. - The compound activates Protein Phosphatase 2A and reduces cancer-linked gene activity while also inhibiting P-glycoprotein 1 to improve daunorubicin retention in leukemia cells. - Research from the University of Surrey suggests combining forskolin with daunorubicin could enable lower chemotherapy doses and reduce severe side effects. - The findings, published in the British Journal of Pharmacology, represent a collaborative effort to develop kinder, more effective treatments for one of the most aggressive cancer types.
- The DYNAMIC-III phase II/III trial demonstrated that ctDNA-negative stage III colon cancer patients have low recurrence risk, supporting ctDNA as a biomarker for tailoring adjuvant therapy. - While overall non-inferiority was not achieved (85.3% vs 88.1% 3-year RFS), ctDNA-guided management significantly reduced oxaliplatin use from 88.6% to 34.8% and decreased grade ≥3 adverse events. - In clinically low-risk tumors (T1-3N1), ctDNA-guided de-escalation showed comparable outcomes to standard therapy, suggesting this subgroup could safely benefit from less intensive treatment. - Expert commentary indicates the trial adds important evidence for better patient selection in adjuvant chemotherapy, though further research is needed to optimize the approach.
- Belzutifan showed a clinically meaningful 2.66-month improvement in quality-adjusted time without symptoms or toxicity (Q-TWiST) compared to everolimus in advanced renal cell carcinoma patients. - The phase 3 LITESPARK-005 trial demonstrated an 11.32% relative gain in Q-TWiST with belzutifan, despite numerically longer time with grade 3/4 toxicity. - Belzutifan patients experienced significantly longer time without symptoms and progression (10.73 vs 6.07 months) driven by prolonged periods without disease progression. - The analysis supports belzutifan's clinical benefit profile, with lead investigator Thomas Powles noting superior response rates, progression-free survival, and quality of life outcomes.
• Final analysis of CALYPSO trial demonstrates significant efficacy with savolitinib-durvalumab combination, showing 53% response rate in MET-driven papillary renal cancer patients. • Study reveals median overall survival of 27.4 months in MET-driven subset, compared to 18 months in the intention-to-treat population. • Novel ctDNA analysis indicates baseline status may predict treatment response, with ctDNA-negative patients showing significantly better survival of 33 months versus 7 months for ctDNA-positive patients.
- The KEYNOTE-522 trial's long-term data reveal a significant overall survival (OS) benefit with pembrolizumab plus chemotherapy in high-risk, early-stage triple-negative breast cancer (TNBC). - At a median follow-up of 75.1 months, the 5-year OS rate was 86.6% in the pembrolizumab arm versus 81.7% in the placebo arm (HR, 0.66; _P_ = .00150). - Event-free survival (EFS) was also significantly improved, with a 60-month EFS rate of 81.2% in the pembrolizumab arm compared to 72.2% in the placebo arm (HR, 0.65). - These findings solidify pembrolizumab's role as a standard treatment component for patients with high-risk, early-stage TNBC, according to Dr. Peter Schmid.
- The NIAGARA trial demonstrated that perioperative durvalumab combined with chemotherapy significantly improves event-free and overall survival in patients with muscle-invasive bladder cancer. - Patients receiving durvalumab showed a 67.8% event-free survival rate at two years, compared to 59.8% in those receiving chemotherapy alone, marking a significant improvement. - The study establishes a new standard of care for perioperative therapy in this patient population, though experts emphasize the need for predictive biomarkers to refine treatment strategies. - Ongoing trials are exploring the role of biomarkers like circulating tumor DNA to guide immunotherapy and personalize bladder cancer treatment after cystectomy.
- The NIAGARA trial demonstrated a significant improvement in event-free survival with the addition of durvalumab to cisplatin-based chemotherapy in muscle-invasive bladder cancer. - The study reported a 25% reduction in the risk of death with the durvalumab combination, marking the first overall survival benefit for immunotherapy in this setting. - Pathological complete response rates saw a 10% increase with the addition of durvalumab, suggesting a potential for less surgery in the future with improved therapies. - Ongoing trials are exploring antibody-drug conjugates in cisplatin-ineligible patients, potentially expanding treatment options and improving outcomes in bladder cancer.
- The KEYNOTE-522 trial demonstrates that adding pembrolizumab to neoadjuvant chemotherapy significantly improves overall survival (OS) in patients with early-stage triple-negative breast cancer (TNBC). - The study showed a 34% reduction in the risk of death with the pembrolizumab combination compared to chemotherapy alone (HR, 0.66), benefiting various patient subgroups. - After a median follow-up of 75 months, event-free survival rates at 5 years were 81% with pembrolizumab plus chemotherapy versus 72% with chemotherapy alone. - The safety profile of pembrolizumab plus chemotherapy remained consistent with previous findings, with no new long-term safety concerns identified.
- Neoadjuvant pembrolizumab combined with chemotherapy, followed by adjuvant pembrolizumab, significantly improves overall survival in early-stage triple-negative breast cancer (TNBC). - The KEYNOTE-522 trial demonstrated a 34% reduction in the risk of death with the pembrolizumab regimen compared to placebo in TNBC patients. - At a median follow-up of 75.1 months, the 5-year overall survival rate was 86.6% in the pembrolizumab arm versus 81.7% in the placebo arm. - Patients achieving pathological complete response (pCR) showed an overall survival benefit, irrespective of the treatment arm, highlighting the importance of early response.
- Phase III trials show that combining immunotherapy drugs with chemotherapy improves survival in triple-negative breast cancer (TNBC) and muscle-invasive bladder cancer. - Pembrolizumab combined with chemotherapy reduces the risk of cancer recurrence and improves overall survival in high-risk early-stage TNBC patients. - Durvalumab with chemotherapy increases the cure rate in patients with muscle-invasive bladder cancer, marking a significant advancement in treatment. - These findings establish new standards of care for these aggressive cancers, offering improved outcomes for patients.
